Hocoia

Hocoia is a France-based company specializing in mobile health solutions that enhance access to healthcare services through innovative mobile medical units and telemedicine, bridging gaps in service delivery for patients and professionals alike. Founded in 2021 in Strasbourg, France, Hocoia focuses on providing mobile health services. It has not undergone any notable pivots or changes in strategy. The company has secured a total of EUR 3.

000 mn in funding from investors including Angels Santé, Bpifrance, Phenomenelle Angels, and Sowefund, with the latest funding round occurring in December 2025. Hocoia's core offering revolves around mobile medical units, aimed at increasing healthcare accessibility. Hocoia specializes in mobile health solutions aimed at enhancing access to healthcare services for patients, healthcare professionals, communities, and businesses. Their core product offerings include mobile medical units known as Médicobus, which are equipped with advanced technology to facilitate immediate and accessible healthcare delivery.

Hocoia also provides MammoBus units specifically designed for breast cancer screening, which can be deployed in corporate and community settings. Their services extend to telemedicine solutions, ensuring that patients can connect with healthcare professionals remotely, thus overcoming geographical barriers. The primary customer base encompasses healthcare organizations, municipalities, and enterprises primarily located across France, including urban and rural areas experiencing medical service shortages. Hocoia generates revenue through direct partnerships with healthcare institutions, municipalities, and corporate clients who utilize their mobile health solutions for various preventative care initiatives.

The company operates on a structured transaction model, where clients can engage services via long-term partnerships or single-event contracts that include telehealth consultations, mobile screenings, and health awareness programs. The pricing structure involves fees associated with the deployment of mobile units and telemedicine services, catering to the specific needs of clients while ensuring comprehensive healthcare solutions are delivered efficiently. The flagship offerings, such as the Médicobus and MammoBus, serve as key components in Hocoia's revenue-generating strategy, allowing for both direct service provision to end-users and collaborative ventures with local health authorities. In December 2025, Hocoia raised EUR 3.

000 mn in venture funding to support its nationwide rollout and enhance regional coverage. The company plans to expand its prevention and screening programs and scale mobile health technologies. Upcoming products include enhanced versions of existing mobile units, with aims to launch in the second half of 2026. Hocoia targets growth in urban centers and rural areas across France, leveraging the recent funding to accelerate the development and deployment of innovative health solutions.